The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Hypercalcemia: A Review
Abstract
Importance: Hypercalcemia affects approximately 1% of the worldwide population. Mild hypercalcemia, defined as total calcium of less than 12 mg/dL (<3 mmol/L) or ionized calcium of 5.6 to 8.0 mg/dL (1.4-2 mmol/L), is usually asymptomatic but may be associated with constitutional symptoms such as fatigue and constipation in approximately 20% of people. Hypercalcemia that is severe, defined as total calcium of 14 mg/dL or greater (>3.5 mmol/L) or ionized calcium of 10 mg/dL or greater (≥2.5 mmol/L) or that develops rapidly over days to weeks, can cause nausea, vomiting, dehydration, confusion, somnolence, and coma. Observations: Approximately 90% of people with hypercalcemia have primary hyperparathyroidism (PHPT) or malignancy. Additional causes of hypercalcemia include granulomatous disease such as sarcoidosis, endocrinopathies such as thyroid disease, immobilization, genetic disorders, and medications such as thiazide diuretics and supplements such as calcium, vitamin D, or vitamin A. Hypercalcemia has been associated with sodium-glucose cotransporter 2 protein inhibitors, immune checkpoint inhibitors, denosumab discontinuation, SARS-CoV-2, ketogenic diets, and extreme exercise, but these account for less than 1% of causes. Serum intact parathyroid hormone (PTH), the most important initial test to evaluate hypercalcemia, distinguishes PTH-dependent from PTH-independent causes. In a patient with hypercalcemia, an elevated or normal PTH concentration is consistent with PHPT, while a suppressed PTH level (<20 pg/mL depending on assay) indicates another cause. Mild hypercalcemia usually does not need acute intervention. If due to PHPT, parathyroidectomy may be considered depending on age, serum calcium level, and kidney or skeletal involvement. In patients older than 50 years with serum calcium levels less than 1 mg above the upper normal limit and no evidence of skeletal or kidney disease, observation may be appropriate. Initial therapy of symptomatic or severe hypercalcemia consists of hydration and intravenous bisphosphonates, such as zoledronic acid or pamidronate. In patients with kidney failure, denosumab and dialysis may be indicated. Glucocorticoids may be used as primary treatment when hypercalcemia is due to excessive intestinal calcium absorption (vitamin D intoxication, granulomatous disorders, some lymphomas). Treatment reduces serum calcium and improves symptoms, at least transiently. The underlying cause of hypercalcemia should be identified and treated. The prognosis for asymptomatic PHPT is excellent with either medical or surgical management. Hypercalcemia of malignancy is associated with poor survival. Conclusions and Relevance: Mild hypercalcemia is typically asymptomatic, while severe hypercalcemia is associated with nausea, vomiting, dehydration, confusion, somnolence, and coma. Asymptomatic hypercalcemia due to primary hyperparathyroidism is managed with parathyroidectomy or observation with monitoring, while severe hypercalcemia is typically treated with hydration and intravenous bisphosphonates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Wilhelm, S. M., Wang, T. S., Ruan, D. T., Lee, J. A., Asa, S. L., Duh, Q.-Y., Doherty, G. M., Herrera, M. F., Pasieka, J. L., Perrier, N. D., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.2310 · Cited by 1,343
Interpretation of Serum Calcium in Patients with Abnormal Serum Proteins
Payne, R. B., Little, A. J., Williams, R. B., & Milner, J. R. (1973) · BMJ · doi:10.1136/bmj.4.5893.643 · Cited by 945
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery
Silverberg, S. J., Shane, E., Jacobs, T. P., Siris, E., & Bilezikian, J. P. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411701 · Cited by 845
Self-citationNussbaum, S. R., Zahradnik, R. J., Lavigne, J. R., Brennan, G. L., Nozawa-Ung, K., Kim, L. Y., Keutmann, H. T., Wang, C. A., Potts, J. T., & Segre, G. V. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.8.1364 · Cited by 808
Renal Control of Calcium, Phosphate, and Magnesium Homeostasis
Blaine, J., Chonchol, M., & Levi, M. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09750913 · Cited by 787
Rubin, M. R., Bilezikian, J. P., McMahon, D. J., Jacobs, T., Shane, E., Siris, E., Udesky, J., & Silverberg, S. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1215 · Cited by 593
Self-citationParathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Bollerslev, J., Jansson, S., Mollerup, C. L., Nordenström, J., Lundgren, E., Tørring, O., Varhaug, J.-E., Baranowski, M., Aanderud, S., Franco, C., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1836 · Cited by 368
Eastell, R., Brandi, M. L., Costa, A. G., D'Amour, P., Shoback, D. M., & Thakker, R. V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1414 · Cited by 341
The diagnosis and management of hypercalcaemia
Minisola, S., Pepe, J., Piemonte, S., & Cipriani, C. (2015) · BMJ · doi:10.1136/bmj.h2723 · Cited by 275
Denosumab for Treatment of Hypercalcemia of Malignancy
Hu, M. I., Glezerman, I. G., Leboulleux, S., Insogna, K., Gucalp, R., Misiorowski, W., Yu, B., Zorsky, P., Tosi, D., Bessudo, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1001 · Cited by 203
Mundy, G. R., & Guise, T. A. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)80047-2 · Cited by 197
Prevalence of hypercalcaemia in a health survey: a 14‐year follow‐up study of serum calcium values
PALMÉR, M., JAKOBSSON, S., ÅKERSTRÖM, G., & LJUNGHALL, S. (1988) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1988.tb01163.x · Cited by 185
Malihi, Z. A., Wu, Z., Stewart, A. W., Lawes, C. M. M., & Scragg, R. K. R. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.134981 · Cited by 171
Parathyroid Hormone Activates TRPV5 via PKA-Dependent Phosphorylation
de Groot, T., Lee, K., Langeslag, M., Xi, Q., Jalink, K., Bindels, R. J. M., & Hoenderop, J. G. J. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080873 · Cited by 168
Warrell, R. P., ISRAEL, R., FRISONE, M., SNYDER, T., GAYNOR, J. J., & BOCKMAN, R. S. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-5-669 · Cited by 163
Martín, M., Bell, R. H., Bourgeois, H. P., Brufsky, A., Diel, I., Eniu, A. E., Fallowfield, L. J., Fujiwara, Y., Jassem, J., Paterson, A. H. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3310 · Cited by 149
Vitamin D supplementation: upper limit for safety revisited?
Rizzoli, R. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01678-x · Cited by 127
Pecherstorfer, M., Herrmann, Z., Body, J., Manegold, C., Degardin, M., Clemens, M., Thurlimann, B. J. K., Tubiana-Hulin, M., Steinhauer, E. U., Eijkeren, M. V., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.268 · Cited by 124
Mechanisms of osteolytic and osteoblastic skeletal lesions
Roodman, G. D., & Silbermann, R. W. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.122 · Cited by 95
Lundstam, K., Heck, A., Mollerup, C., Godang, K., Baranowski, M., Pernow, Y., Varhaug, J. E., Hessman, O., Rosén, T., Nordenström, J., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3441 · Cited by 95
Management of Primary Hyperparathyroidism
Bilezikian, J. P., Silverberg, S. J., Bandeira, F. A. F., Cetani, F., Chandran, M., Cusano, N. E., Ebeling, P. R., Formenti, A. M., Frost, M., Gosnell, J. E., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4682 · Cited by 90
Pecherstorfer, M., Steinhauer, E. U., Rizzoli, R., Wetterwald, M., & Bergstr�m, B. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0477-1 · Cited by 83
Denosumab for Management of Parathyroid Carcinoma-Mediated Hypercalcemia
Vellanki, P., Lange, K., Elaraj, D. M., Kopp, P. A., & Muayed, M. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3031 · Cited by 78
Sato, T., Courbebaisse, M., Ide, N., Fan, Y., Hanai, J., Kaludjerovic, J., Densmore, M., Yuan, Q., Toka, H. R., Pollak, M. R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616733114 · Cited by 77
Lian, I. A., & Åsberg, A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017703 · Cited by 76
Griebeler, M. L., Kearns, A. E., Ryu, E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3964 · Cited by 72
Calcitriol-Mediated Hypercalcemia: Causes and Course in 101 Patients
Donovan, P. J., Sundac, L., Pretorius, C. J., dʼEmden, M. C., & McLeod, D. S. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2016 · Cited by 70
van de Graaf, S. F. J., Boullart, I., Hoenderop, J. G. J., et al. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.03.029 · Cited by 70
The incidence and causes of hypercalcaemia
DENT, D. M., Miller, J. L., Klaff, L. J., et al. (1987) · Postgraduate Medical Journal · doi:10.1136/pgmj.63.743.745 · Cited by 67
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection
Pecherstorfer, M., Ludwig, H., Schlosser, K., Buck, S., Huss, H., & Body, J. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110506 · Cited by 64
Hypercalcemia associated with cosmetic injections: a systematic review
Tachamo, N., Donato, A. A., Timilsina, B., Nazir, S., Lohani, S., Dhital, R., & Basnet, S. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0938 · Cited by 62
Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury
Massagli, T. L., & Cardenas, D. D. (1999) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(99)90050-3 · Cited by 57
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
Rambhia, P. H., Reichert, B., Scott, J. F., Feneran, A. N., Kazakov, J., Honda, K. S., Koon, H. B., & Gerstenblith, M. R. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01490-2 · Cited by 57
Axelsson, K. F., Wallander, M., Johansson, H., Harvey, N. C., Vandenput, L., McCloskey, E. V., Liu, E., Kanis, J. А., Litsne, H., & Lorentzon, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.15396 · Cited by 57
Cicci, J. D., Buie, L. W., Bates, J. S., & van Deventer, H. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.07.005 · Cited by 49
Hypercalcemia following discontinuation of denosumab therapy: A systematic review
Horiuchi, K., Kobayashi, E., Mizuno, T., Susa, M., & Chiba, K. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101148 · Cited by 49
Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy
Uppal, N. N., Workeneh, B., Rondon‐Berrios, H., & Jhaveri, K. D. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14671121 · Cited by 49
Pretorius, M., Lundstam, K., Heck, A., Fagerland, M. W., Godang, K., Mollerup, C., Fougner, S. L., Pernow, Y., Aas, T., Hessman, O., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4416 · Cited by 49
Chandran, M., Bilezikian, J. P., Lau, J., Rajeev, R., Yang, S. P., Samuel, M., & Parameswaran, R. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09694-6 · Cited by 48
Zhang, J., Huan, Y., Leibensperger, M. R., Seo, B., & Song, Y. (2022) · Kidney360 · doi:10.34067/kid.0006672021 · Cited by 45
Low vitamin D levels have become less common in primary hyperparathyroidism
Walker, M. D., Cong, E., Lee, J. A., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3199-6 · Cited by 41
Self-citationDenosumab for management of severe hypercalcemia in primary hyperparathyroidism
Константиновна, Е. А., Krupinova, J. A., Dobreva, E. A., Gorbacheva, A. M., Евгеньевна, Б. Е., Samsonova, M. D., Elfimova, A. R., & Mokrysheva, N. (2020) · Endocrine Connections · doi:10.1530/ec-20-0380 · Cited by 41
Jiang, L., Cui, X., Ma, H., & Tang, X. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02554-8 · Cited by 38
The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease
Pirklbauer, M., & Mayer, G. J. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr207 · Cited by 34
Schwarz, P. E. H., Sørensen, H. A., Transbøl, I., et al. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.263.2.e195 · Cited by 29
Kazaure, H. S., Thomas, S. M., Scheri, R. P., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.03.026 · Cited by 29
Mertz, P., Jeannel, J., Guffroy, A., Lescuyer, S., Korganow, A., Rondeau-Lutz, M., & Weber, J. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102824 · Cited by 25
Pathophysiology of Hypercalcemia
Goltzman, D. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.07.008 · Cited by 24
Regulation of Calcium Homeostasis
Vautour, L., & Goltzman, D. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch22 · Cited by 18
CLINICAL FINDINGS IN PATIENTS WITH HYPERCALCAEMIA
Heedman, P., & Stenström, G. (1973) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1973.tb10557.x · Cited by 17
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105942 · Cited by 17
Wanchoo, R., Sakhiya, V., & Jhaveri, K. D. (2021) · Kidney International · doi:10.1016/j.kint.2021.06.001 · Cited by 17
Exercise-induced hypercalcemia and vasopressin-mediated bone resorption
Senda, M., Hamano, T., Fujii, N., Ito, T., Sakaguchi, Y., Matsui, I., Isaka, Y., & Moriyama, T. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06030-1 · Cited by 8
Masri, D. E., Jamil, Y., & Fares, J. E. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2021.07.002 · Cited by 6
Cited by
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Metadata
- Authors
- Walker, M. D., & Shane, E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-10-25
- Volume
- 328
- Issue
- 16
- Pages
- 1624
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4307208491
- Cited by
- 260
- References
- 58
- FWCI
- 24.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.